公司业绩 - GE HealthCare Technologies在2024年的利润和现金流有望大幅增长[1] - 公司的营收增长主要受益于有机增长，价格和销量的提升[3] - 公司的药物诊断部门表现最佳，营收增长25%[4] - 尽管营收增长，但底线业绩并不理想，净利润下降[6] - 公司发布2024年的指导意见，预计有机营收将增长约4%，调整后的每股收益也有望提升[8] 投资价值 - GE HealthCare Technologies相对于类似公司来说，股价相对便宜，具有投资价值[9] - 预计2024年公司有望实现巨大改善，股价相对其他类似公司具有吸引力[13] 业务发展 - 公司与OSF HealthCare建立战略合作联盟，收购MIM Software，积极寻求业务机会[12]

ORLANDO, Fla.--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) will showcase its industry-leading portfolio of artificial intelligence (AI)-enabled medical devices and digital solutions in Booth 2500 at the Health Information and Management Systems Society (HIMSS) Global Health Conference and Exhibition in Orlando, FL from March 11-15, 2024. In the U.S., clinicians spend nearly twice as much time working with electronic health records as working with patients.i This challenge is only increasing as healthcare ...

GE Healthcare (GEHC 0.53%) had an excellent start to life as a stand-alone company in 2023, and the trend has continued in 2024 with a 15% gain already this year.While it's easy to think of this recent spinoff from General Electric as a mature healthcare business, there is actually an investment case to be made for the company based on its growth opportunities. And it's those opportunities that are leading the stock to outperform.Here's why GE Healthcare is an attractive stock for investors now.GE Healthcar ...

GE HealthCare Technologies Inc. (GEHC) recently announced its advancements in its ultrasound business with the launch of its next-level LOGIQ ultrasound portfolio. This includes the new LOGIQ Totus, which highlights the company’s progress in advancing precision care.The LOGIQ E10 Series, LOGIQ Fortis and LOGIQ Totus are currently available in key countries worldwide. GE HealthCare was scheduled to demonstrate the next-generation LOGIQ portfolio at the European Congress of Radiology, held between Feb 28 and ...

Shares in leading healthcare company GE HealthCare Technologies (GEHC 1.58%) soared by 24.4% in February, according to data provided by S&P Global Market Intelligence. There's little doubt over the catalyst for the move; it comes from an excellent earnings report released in the first week of the month.GE HealthCare's growth potentialThe investment case for GE HealthCare is based on the idea that, now that it's a stand-alone company, management is free to realize its full potential. That potential lies in o ...

文章核心观点 - Zacks Premium是一个可以帮助投资者更自信地投资的研究服务 [1][2] - Zacks Style Scores是一个根据价值、成长和动量三大因素评估股票的独特指标体系 [3][4] - Zacks Rank是一个基于盈利预期变化的股票评级模型,与Style Scores配合使用可以帮助投资者选择最有潜力的股票 [9][10][12][13][14] - GE HealthCare Technologies (GEHC)是一家医疗技术公司,目前在Zacks Rank和Style Scores方面表现不错,值得关注 [15][16][17] 公司概况 - GE HealthCare Technologies是一家医疗技术、诊断和数字解决方案提供商,于2023年1月3日从通用电气公司分拆而来 [15] 财务表现 - GEHC的2024财年每股收益预期为4.30美元,较之前预期上调0.06美元 [17] - GEHC过去平均每次财报公布时的实际每股收益都高于预期9% [17] 估值情况 - GEHC的预测市盈率为21.23倍,对于价值投资者来说估值较为吸引 [16]

CHICAGO--(BUSINESS WIRE)--GE HealthCare (Nasdaq: GEHC) today announced its latest innovation in ultrasound with the launch of its next-level LOGIQ ultrasound portfolio—including the new LOGIQ Totus—highlighting the company’s progress in advancing precision care. LOGIQ, is a trusted companion in general ultrasound imaging and has supported clinicians in delivering high-quality, patient-driven innovation for more than 30 years. The elevated LOGIQ portfolio innovative new features and advanced artificial intel ...

GE HealthCare Technologies Inc. (GEHC) and Biofourmis recently announced their collaboration to boost at-home health care that is easily accessible to assist patients' transitions out of hospitals.As a result of this collaboration, the companies are likely to enable more patients to return home sooner and provide them with a high-quality, at-home alternative to facility-based care, all while promoting healthy behaviors through remote patient management.Price PerformanceFor the past six months, GEHC’s shares ...

Collaboration supports the patient journey across the care continuum and eases transitions and care from the hospital to homeCHICAGO and BOSTON, Feb. 26, 2024 /PRNewswire/ -- GE HealthCare (Nasdaq: GEHC) and Biofourmis have announced a strategic collaboration aimed at enhancing continuity of care by enabling safe, effective, and accessible care in the home to support the patient journey beyond the hospital setting. The collaboration leverages the combined expertise of two market leaders to scale and deliver ...

合作与战略发展 - GE HealthCare Technologies Inc.最近与OSF HealthCare和Pointcore, Inc.达成战略合作联盟，旨在提高临床和运营效率，标准化护理模式，改善OSF HealthCare的患者结果[1] - 此次合作预计将加强GE HealthCare在核医学、肿瘤学和放射学等多个护理领域的地位，并推动其成像业务[3] - 合作的理念在于加强GE HealthCare、OSF HealthCare和Pointcore在新技术系统、数字工具和资源、服务和支持等方面的合作，以促进创新投资和提高患者护理[4] - GE HealthCare最近宣布与MedQuest Associates展开为期三年的合作，通过提供GE HealthCare的先进技术和MedQuest所需的基础设施和资源，提供增强的患者护理[9] 技术创新与产品发展 - OSF HealthCare将成为美国首家实施GE HealthCare新版数字专家访问与远程扫描的医疗系统，这是首个FDA 510(k)认证的设备，可在GE HealthCare磁共振成像设备上实现远程患者扫描[5] - GE HealthCare宣布其最新的心电生理学（EP）创新产品Prucka 3与CardioLab EP记录系统，以帮助临床医生诊断和治疗心律失常[11] 业绩与股价表现 - GE HealthCare宣布其2023年第四季度业绩，收入在报告和有机基础上均有显著增长，成像部门的收入也表现强劲[10] - GE HealthCare股价在过去一年中上涨了18.7%，远高于行业的8.9%下跌和标普500指数的25.4%增长[12]